Bone infections usually begin in the cancellous bone of the metatarsal bones, leading to osteomyelitis. Patients with poorly managed diabetic foot infection (DFI) can experience progression to osteomyelitis. OM can be characterized as acute or chronic.

Definitions
Osteomyelitis (OM) is defined as an infection of the cancellous or cortical bone caused by any of three general etiologies—hematogenous seeding, spread of contiguous infection, or association with vascular insufficiency [Glaudemans 2019, Bevilacqua 2007]. Hematogenous seeding of the bone is often seen in pediatric and geriatric patients [Lew 2004]. Hematogenous seeding of the bone is generally considered the most common etiology of osteomyelitis in the pediatric patient [Glaudemans 2019, Bevilacqua 2007].

Objectives
1) Define osteomyelitis and briefly describe clinical presentation and diagnostics
2) Identify causative microbes based on osteomyelitis etiology
3) Interpret literature evaluating medical management of osteomyelitis, with a focus on oral antimicrobial therapy
4) Analyze factors affecting therapy choice and treatment duration

Hematogenous seeding is generally considered the most common etiology of osteomyelitis in the pediatric patient.

Glaudemans 2019, Lew 2004].

Patients with uncontrolled diabetes often present with lower extremity ulcers secondary to peripheral neuropathy and vascular insufficiency [Lew 2004]. Ulcerations and persistent hyperglycemia allow bacteria to colonize and infect the bone [Glaudemans 2019, Bevilacqua 2007]. Patients with poorly managed diabetic foot infection (DFI) can experience progression to osteomyelitis [Bevilacqua 2007, Lew 2004]. OM can be characterized as acute or chronic [Lew 2004].

Continued on page 138
Osteomyelitis (from page 137)

Signs, Symptoms, and Presentation

The immune response to the infection leads to inflammation, bone destruction, and clinical signs associated with osteomyelitis [Bevilacqua 2007, Lew 2004]. Signs and symptoms of infection include fever, malaise, and pain [Bevilacqua 2007]. Chronic infection and inflammation can lead to bone necrosis and sequestrum or sinus tract formation [Lew 2004].

Diagnosis

Diagnostics of osteomyelitis includes clinical examination, plain radiography, magnetic resonance imaging (MRI), three-phase bone scan, white blood cell scans, and probe-to-bone test. Although MRI can reveal edema and inflammation, bone histology and culture are required for definitive diagnosis [Bevilacqua 2007]. Blood cultures are also recommended in patients with suspicion of hematogenous spread or systemic infection.

Monitoring laboratory parameters trends may aid in OM diagnosis and management. A study performed at our institution delineated C-reactive protein (CRP) greater than 3.2 and erythrocyte sedimentation rate (ESR) greater than 76 to be attributable to OM.

Microbiology

The two most common pathogenic organisms in OM are Staphylococcus aureus followed by Streptococcus spp. S. aureus is hardy and particularly difficult to treat due to its ability to form biofilm and predilection to intracellular persistence [Lew 2004]. Post-traumatic and post-surgical infections may be polymicrobial or due to nosocomial Gram-positive or Gram-negative bacteria [Lew 2004]. Vertebral OM may be caused by either Gram-positive or Gram-negative species or M. tuberculosis [Berbari 2015, Lew 2004]. Various Gram-positive, Gram-negative, or anaerobic bacteria (acnes) are also potential causative pathogens. S. epidermidis is increasingly resistant to methicillin (MRSE) and other common empiric antimicrobials, including fluoroquinolones and TMP-SMX [Lew 2004]. Penicillins and narrow-spectrum cephalosporins are first-line against Streptococci with linezolid and clindamycin considered alternatives. Oral treatment options against Enterococci, including vancomycin-resistant strains, include linezolid, tedizolid, and tetracyclines [Fraimow 2009].

Gram-negative or polymicrobial infections may be encountered in susceptible patients, such as those with recent healthcare exposure, diabetes, trauma, or surgery. Limited therapy upon symptomatic improvement and availability of culture and sensitivity reports [Lipsky 2012, Khan 2012]. An increasing body of literature questions the lengthy duration of intravenous drug administration and supports even earlier transition to oral therapy [Li 2019].

In the recently published OVIVA study, patients in the oral treatment arm had reduced hospital length of stay compared to IV treatment (14 vs. 11 days; p < 0.001) [Li 2019]. Treatment with oral medications increases patient convenience, decreases economic burden, and prevents potential complications of long-term venous access, including catheter occlusion.

Bone histology and culture in addition to clinical judgment, are needed for a definitive diagnosis of osteomyelitis.
and infection, found to occur in up to 9% of patients [Li 2019, Khan 2012].

**Treatment Options—Oral**

Drug-specific factors affecting oral antimicrobial choice include: protein binding, bioavailability, volume of distribution, lipophilicity, molecular weight, charge, and bone penetration. As Fraimow and colleagues highlight, interpretation of standard minimum inhibitory concentration (MIC) results is based on achievable serum concentrations and may not be reliable depending on active, free drug concentrations in the bone [Fraimow 2009]. A review by Thabit, et al. provides cortical and cancellous bone concentrations compared to MIC breakpoints of commonly encountered pathogens in OM [Thabit 2019]. Drug distribution to the bone often may be unpredictable. Infected and inflamed bone may lead to hyperemia and increased drug presence. However, avascular and necrotic bone, presence of foreign material, and biofilm prevent adequate penetration to site of infection due to lack of blood flow and distribution [Lew 2004, Kim 2014]

Highly bioavailable oral antimicrobials should be utilized in management of OM [Lipsky 2012]. The dose and frequency should be adapted to maximize pharmacokinetic and pharmacodynamic parameters of each agent. Potential drug-specific adverse drug reactions (ADRs), including C. difficile infection, also affect treatment choice, especially at the high doses needed to effective-ly treat OM [Khan 2012, Fraimow 2009]. Lastly, it is imperative to determine whether monotherapy or combination therapy should be used. Especially in the cases of foreign material associated bone and joint infection due to MRSA, monotherapy was associated with treatment failure [Kim 2014, Lew 2004].

The pharmacodynamic parameter associated with efficacy is time above MIC; however, achieving an adequate Cmax above MIC is vital. Oral TMP-SMX is not effective against P. aeruginosa.

Dosing for management of MRSA OM ranges from 4–7 mg TMP/kg/dose every 12 hours orally. Higher doses of up to 10 mg/kg TMP (approximately 2 TMP-SMX double-strength tablets (160 mg TMP/800 mg SMX) twice daily) may increase bone penetration and monotherapy treatment success [Kim 2014]. These doses, however, are likely to predispose patients to ADRs, including hyperkalemia, hemolysis in patients with G6PD deficiency, pancytopenia, nephrotoxicity, and gastrointestinal distress. Severe dermatologic reactions, including Stevens-Johnson syndrome may also occur with this agent. Plasma protein binding is estimated at 44% for TMP and 70% for sulfamethoxazole. Oral TMP-SMX is considered highly bioavailable—IV to oral dose conversion is 1:1 [Klepser 1996]. TMP-SMX distributes extensively into body tissues, making it an appealing choice in treatment of OM. Bone penetration is 50% and 15% of serum concentrations for TMP and SMX, respectively [Spellberg 2012].

**Fluoroquinolones**

Fluoroquinolones are bactericidal agents that inhibit bacterial topoisomerase IV and DNA gyrase, leading to disruption of DNA processing. Commonly employed agents in the class include ciprofloxacin, levofloxacin, and moxifloxacin. Spectrum of activity includes MSSA, Streptococci, E. coli, K. pneumoniae, S. marcescens, Enterobacter spp., and P. aeruginosa. The widespread use of fluoroquinolones in infectious diseases practice has led to promulgation of resistance to these agents. Monotherapy may be considered against susceptible Gram-positive and Gram-negative isolates. Co-administration with rifampin is recommended to curb resistance development and enhance bactericidal activity against Gram-positive pathogens. High doses of each oral agent are recommended for management of OM, such as ciprofloxacin 500 mg–750 mg every 12 hours, levofloxacin 750 mg once daily, and moxifloxacin 400 mg once daily. Clinicians should monitor for musculoskeletal (tendonitis, muscle weakness), central nervous system (hallucinations, agitation), and cardiac (QT-prolongation) toxicities.

Potentially significant drug interactions exist with cations and antiarrhythmic drugs [Khan 2012]. Ciprofloxacin and levofloxacin protein binding range from 20 to 40% in plasma. The pharmacodynamic parameters associated with efficacy are Cmax and AUC to MIC ratio. aeruginosa. Rapid absorption from the GI tract and high volumes of distribution allow appreciable drug concentration in deep tissues, including bone [Khan 2012]. Mean bone to serum ratios range from 27–120% for oral ciprofloxacin and 43–105% for oral moxifloxacin, generally exceeding the Staphylococci MIC90 [Spellberg 2012, Kim 2014, Landersdorfer 2009]. These agents are especially enticing for use against S. aureus due to their ability to penetrate osteoblasts where this pathogen often persists [Landersdorfer 2009]. Fluoroquinolone treatment success rates in OM trials have ranged from 50-77% [Greenberg 2000, Gentry 1990, Khan 2012, Zimmerli 1998, Spellberg 2012]. Delafloxacin was recently approved by the US Food and
**Osteomyelitis (from page 139)**

Drug Administration (FDA). This agent demonstrates in vitro activity against MRSA, in addition to the previously noted pathogens. Delafloxacin is approved for treatment of acute vancomycin-resistant isolates), and is indicated for treatment of ABSSSI, nosocomial pneumonia, and VRE infections. Oral and intravenous dosing are equivalent (100% bioavailability) at 600 mg every 12 hours. Bone to serum ratio of linezolid ranges from 37–51%, with bone concentrations exceeding Staphylococci MIC90 [Spellberg 2012, Kim 2014, Landersdorfer 2009]. Treatment success rates range from 55 to 100% in Gram-positive OM and are comparable to ampicillin-sulbactam for DFI [Nguyen 2009, Lipsky 2004, Kim 2014].

Linezolid has generally poor activity against biofilm and should be combined with a biofilm-active agent, such as rifampin, if indicated. ADRs associated with linezolid include myelosuppression (anemia, thrombocytopenia), peripheral and optic neuropathy, and hypoglycemia. One study reported side effects in over 50% of patients, especially in those with treatment duration greater than two weeks. Treatment discontinuation rates were up to 30% [Senn- neville 2006].

Linezolid’s inhibition of monoamine oxidase can lead to drug-drug interactions with antipsychotics, anti-depressives, and anxiolytic agents. Plasma protein binding of linezolid is approximately 30%, and volume of distribution is 0.65 L/kg. The pharmacodynamic parameter associated with efficacy is time above MIC. The pharmacodynamic parameter associated with efficacy is Cmax to serum ratio of linezolid ranges approximately 30%, and volume of distribution was estimated at 40 to 45% [Spellberg 2012, Landersdorfer 2009].

**Clindamycin**

Clindamycin is a bacteriostatic lincosamide that acts on the 50S ribosomal subunit inhibiting bacterial protein synthesis. Its spectrum of activity includes CA-MRSA, Streptococcus spp., and anaerobes, including Peptostreptococcus spp. and Prevotella spp. Clindamycin has shown efficacy in treatment of pediatric and adult OM. Oral doses in treatment of OM range from 300—450 mg every 6 hours to 600 mg every 8 hours, with higher doses preferred, if tolerated. Adverse reactions associated with clindamycin include gastrointestinal distress, elevated liver function values, and dermatologic reactions. Clindamycin demonstrates greater than 90% plasma protein binding and a bioavailability of 90%. The pharmacodynamic parameter associated with efficacy is AUC to MIC. Of note, S. aureus may display inducible clindamycin-resistance that should be tested for using the erythromycin D-test [Fraimow 2009]. Traditionally, clindamycin bone penetration ranges were estimated at 40 to 70% of serum concentrations, though recent literature suggest ratios closer to 21—45% [Spellberg 2012, Landersdorfer 2009].

**Oxazolidinones**

Oxazolidinones inhibit bacterial protein synthesis by binding to the 23S ribosomal subunit. Linezolid is the most commonly employed agent in this class. Its spectrum of activity includes MRSA, Streptococcus spp., and Enterococci (including from 37–51%, with bone concentrations exceeding Staphylococci MIC90 [Spellberg 2012, Kim 2014, Landersdorfer 2009]. Treatment success rates range from 55 to 100% in Gram-positive OM and are comparable to ampicillin-sulbactam for DFI [Nguyen 2009, Lipsky 2004, Kim 2014].

Linezolid has generally poor activity against biofilm and should be combined with a biofilm-active agent, such as rifampin, if indicated. ADRs associated with linezolid include myelosuppression (anemia, thrombocytopenia), peripheral and optic neuropathy, and hypoglycemia. One study reported side effects in over 50% of patients, especially in those with treatment duration greater than two weeks. Treatment discontinuation rates were up to 30% [Sennneville 2006].

Linezolid’s inhibition of monoamine oxidase can lead to drug-drug interactions with antipsychotics, anti-depressives, and anxiolytic agents. Plasma protein binding of linezolid is approximately 30%, and volume of distribution is 0.65 L/kg. The pharmacodynamic parameter associated with efficacy is time above MIC. The pharmacodynamic parameter associated with efficacy is Cmax to serum ratio of linezolid ranges approximately 30%, and volume of distribution was estimated at 40 to 45% [Spellberg 2012, Landersdorfer 2009].

**Clindamycin**

Clindamycin is a bacteriostatic lincosamide that acts on the 50S ribosomal subunit inhibiting bacterial protein synthesis. Its spectrum of activity includes CA-MRSA, Streptococcus spp., and anaerobes, including Peptostreptococcus spp. and Prevotella spp. Clindamycin has shown efficacy in treatment of pediatric and adult OM. Oral doses in treatment of OM range from 300—450 mg every 6 hours to 600 mg every 8 hours, with higher doses preferred, if tolerated. Adverse reactions associated with clindamycin include gastrointestinal distress, elevated liver function values, and dermatologic reactions. Clindamycin demonstrates greater than 90% plasma protein binding and a bioavailability of 90%. The pharmacodynamic parameter associated with efficacy is AUC to MIC. Of note, S. aureus may display inducible clindamycin-resistance that should be tested for using the erythromycin D-test [Fraimow 2009]. Traditionally, clindamycin bone penetration ranges were estimated at 40 to 70% of serum concentrations, though recent literature suggest ratios closer to 21—45% [Spellberg 2012, Landersdorfer 2009].

**Oxazolidinones**

Oxazolidinones inhibit bacterial protein synthesis by binding to the 23S ribosomal subunit. Linezolid is the most commonly employed agent in this class. Its spectrum of activity includes MRSA, Streptococcus spp., and Enterococci (including

**Rifampin demonstrates greatest efficacy against biofilms and foreign material-associated osteomyelitis.**

bacterial skin and skin structure infections (ABSSSI). Its role in management of OM remains to be elucidated.

**Clindamycin**

Clindamycin is a bacteriostatic lincosamide that acts on the 50S ribosomal subunit inhibiting bacterial protein synthesis. Its spectrum of activity includes CA-MRSA, Streptococcus spp., and anaerobes, including Peptostreptococcus spp. and Prevotella spp. Clindamycin has shown efficacy in treatment of pediatric and adult OM. Oral doses in treatment of OM range from 300—450 mg every 6 hours to 600 mg every 8 hours, with higher doses preferred, if tolerated. Adverse reactions associated with clindamycin include gastrointestinal distress, elevated liver function values, and dermatologic reactions. Clindamycin demonstrates greater than 90% plasma protein binding and a bioavailability of 90%. The pharmacodynamic parameter associated with efficacy is AUC to MIC. Of note, S. aureus may display inducible clindamycin-resistance that should be tested for using the erythromycin D-test [Fraimow 2009]. Traditionally, clindamycin bone penetration ranges were estimated at 40 to 70% of serum concentrations, though recent literature suggest ratios closer to 21—45% [Spellberg 2012, Landersdorfer 2009].

**Oxazolidinones**

Oxazolidinones inhibit bacterial protein synthesis by binding to the 23S ribosomal subunit. Linezolid is the most commonly employed agent in this class. Its spectrum of activity includes MRSA, Streptococcus spp., and Enterococci (including

**No oral beta-lactam in the U.S. possesses clinically relevant activity against MRSA or P. aeruginosa.**

available regarding tedizolid’s bone penetration [Si 2017]. Labeled dosing is 200 mg once daily.

**Metronidazole**

Metronidazole is a bactericidal agent that inhibits nucleic acid synthesis by binding to DNA and electron-transport proteins. This agent possesses activity against a myriad of anaerobic pathogens, including Bacteroides and Clostridium spp. Metronidazole is indicated for treatment of many anaerobic infections, including bone and joint infections caused by Bacteroides spp. Possible adverse reactions include convulsive seizures, peripheral neuropathy, dysgeusia, neutropenia, and a disulfiram-like reaction. The pharmacodynamic parameter associated with efficacy is Cmax above MIC. Plasma protein binding is minimal and dosing is equivalent for IV and oral (1:1) at 500 mg every 8 hours due to high bioavailability. Metronidazole bone concentration is similar to serum concentrations, making it an attractive option for oral treatment of anaerobic OM [Spellberg 2012].

**Tetracyclines**

Tetracyclines are bacteriostatic agents that inhibit bacterial protein synthesis through 30S ribosomal subunit binding. Oral tetracyclines, including doxycycline and minocycline, are commonly employed in management of OM. These agents are active against CA-MRSA and are indicated in a variety of infections. Staphylococci generally have greater sensitivity to minocycline compared to doxycycline, although many isolates are sensitive to both [Fraimow 2009]. These agents have greater than 90% bioavailability allowing for equivalent IV to PO conversion. Both agents are highly protein-bound (greater than 90%) and each dosed at 100 mg every 12 hours. Tetracyclines’ extremely high volumes...
Osteomyelitis (from page 140)

of distribution make them effective in OM. The pharmacodynamic parameter associated with efficacy is AUC to MIC. Doxycycline’s bone to serum concentration ranges from 2–86% and depends on the site of infection [Spellberg 2012].

Rifampin

Rifampin, a commonly employed agent in the rifamycin class, inhibits bacterial-specific DNA-dependent RNA polymerase. This agent is commonly an adjunct in managing OM due to its activity against MRSA, ability to penetrate biofilm, and retention of activity against stationary phase Gram-positive organisms [Kim 2014]. Resistance to rifampin can develop rapidly through polymerase mutations and, hence, should not be used as monotherapy. Co-administration of rifampin with another agent, such as a fluoroquinolone or tetracycline, can increase treatment success rates and prevent emergence of resistance to either agent [Fraimow 2009, Zimmerli 1998]. Combination treatment with rifampin achieved treatment success rates of greater than 80%, including foreign material-associated infections. Rifampin has the potential for a myriad of drug-drug interactions due to its induction of drug metabolism and transport enzymes.

Notable side-effects include flu-like symptoms, red-orange discoloration of body fluids, rash, and hematologic and hepatic toxicity [Khan 2012]. Rifampin bioavailability can vary depending on the duration of therapy. Single dose pharmacokinetic studies demonstrate a bioavailability of greater than 90% [Kim 2014, Agrawal 2005]. However, auto-induction of metabolizing enzymes decreases bioavailability to approximately 70% over time [Agrawal 2005]. The optimal dose of rifampin in managing OM is generally cited as 600 mg daily, although 450 mg every 12 hours has also been reported [Fantoni 2019]. Rifampin demonstrates a large volume of distribution, including penetration into bone and central nervous system [Khan 2012]. Rifampin’s bone to serum concentration ratio range from 20–57% according to some studies and approximate its serum levels in others [Spellberg 2012, Landersdorfer 2009].

Beta-lactams

The beta-lactam class, including penicillins, cephalosporins, carbapenems, and monobactams, are among the most effective and commonly prescribed anti-infectives. They exert bactericidal activity by inhibiting cell wall transpeptidation [Khan 2012]. Spectrum of activity varies with inter- and intra-class. Of note, no oral beta-lactam in the U.S. possesses clinically relevant activity against MRSA or P. aeruginosa. Beta-lactam bioavailability is lower than previously reviewed antimicrobials, emphasizing the need to optimize pharmacokinetic and pharmacodynamic parameters. Commonly employed oral beta-lactams include amoxicillin, amoxicillin-clavulanate, (di)cloxacillin, and cephalaxin. The pharmacodynamic parameter associated with efficacy is time above MIC. Plasma protein binding and bioavailability vary greatly depending on the agent. For example, bioavailability for ampicillin ranges from 37–39% compared to 80% for amoxicillin. Bone penetration of these agents relative to serum concentrations are estimated at 10–20% [Fraimow 2009].

Amoxicillin may achieve up to 30% of its serum concentration in the bone (range: <10–31%) compared to 14% for clavulanate [Landersdorfer 2009]. Cephalexin and cepzodoxime achieve 18 and up to 30%, respectively. Maximally tolerated doses should be employed to ensure consistent bone concentrations above the MIC of the target pathogen. For example, amoxicillin 500mg every 8 hours, or amoxicillin-clavulanate 1g every 8 hours to 2g every 12 hours, may be used [Fantoni 2019]. More data are available indicating beta-lactam efficacy in pediatric, hematogenous OM compared to adult, chronic OM [Kim 2014].

Miscellaneous Agents

Data exist regarding utility of other oral antimicrobials, including fosfomycin, fusidic acid, and pristinamycin in treatment of Gram-positive OM. However, these agents were not reviewed due to limited or conflicting data or lack of availability in the U.S.

Combination Therapy

A variable amount of data exists for combination oral treatment of complex bone infections. Examples primarily include: fluoroquinolones, linezolid, TMP-SMX, clindamycin, fusidic acid, and tetracyclines each in combination with rifampin [Kim 2014, Lew 2004]. Please see individual sections above.

Oral TMP-SMX is not effective against P. aeruginosa.

Treatment Duration

Antimicrobial treatment duration is often dependent on outcome of surgical intervention. Intravenous therapy for 4–6 weeks is commonly recommended to ensure adequate serum and bone concentrations during the period of bone revascularization after surgery [Kim 2014, Lew 2004, Mouzopolous 2011]. Current data, however, suggest initial, short-course intravenous therapy (1–2 weeks) during the period of highest bacterial burden followed by oral therapy is appropriate even in the setting of foreign material, assuming adequate surgical intervention [Li 2019, Mouzopolous 2011, Daver 2007]. Success rates of less than 2 weeks intravenous therapy before switching, 2–4 weeks, 4–6 weeks, and greater than 6 weeks were 83%, 72%, 75%, and 66%, respectively (p = 0.68) [Daver 2007].

The Infectious Diseases Society of America (IDSA) recommends the following treatment durations: if infected soft tissue remains, continue bone treatment for 2–4 weeks. If infected bone remains or surgery is not performed, treatment for 6 weeks to greater than 3 months is recommended [Lipsky 2012, Bevilacqua 2007]. OM secondary to MRSA often necessitates...
Osteomyelitis (from page 141)


treatment for 8 weeks or longer. Suppression therapy for months after initial management may also be required, especially in the setting of infected hardware or protheses. In practice, treatment duration often depends on clinical response and correction of laboratory abnormalities, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

Conclusion

Medical management of OM is a constantly evolving landscape. An increasing body of data supports early conversion to oral antimicrobial treatment for bone and joint infections.

Authors’ Note

We would like to acknowledge George Fahoury, DPM and Donald Beggs, MD for their assistance in the preparation, literature review, and critical appraisal of this manuscript.

References


The duration of intravenous antimicrobial treatment of acute osteomyelitis should be based on patient-specific risk factors, clinical response, laboratory parameter normalization, and evaluation of collateral impact of long-term venous access.
Osteomyelitis (from page 142)


1) What is generally considered the most common etiology of osteomyelitis in the pediatric patient?
   A) Vascular insufficiency
   B) Hematogenous seeding
   C) Contiguous—adjacent soft tissue infection
   D) Contiguous—trauma

2) Which of the following pathogens most commonly causes community-acquired osteomyelitis in adults?
   A) Staphylococci
   B) Enterobacteriaceae
   C) Cutibacterium (Propionibacterium) acnes
   D) Pseudomonas aeruginosa

3) Which of the following diagnostic tests, in addition to clinical judgment, are needed for a definitive diagnosis of osteomyelitis?
   A) Plain radiograph
   B) Magnetic resonance imaging
   C) Bone histology and culture
   D) Positive blood cultures

4) Which of the following are potential complications of long-term venous access?
   A) Access site infection
   B) Mechanical or thrombotic occlusion
   C) Increased cost
   D) All of the above

5) Which of the following drug-specific characteristics do NOT greatly impact choice of oral antimicrobial in treatment of osteomyelitis?
   A) Bioavailability
   B) Bone penetration
   C) Half-life
   D) Volume of distribution

6) Potential adverse drug reactions secondary to long-term linezolid therapy include which of the following?
   A) Optic neuropathy
   B) Myelosuppression
   C) Nephrotoxicity
   D) A + B

Continued on page 144
7) Which of the following agents demonstrates greatest efficacy against biofilms and foreign material-associated osteomyelitis?
   A) Cephalexin
   B) Doxycycline
   C) Linezolid
   D) Rifampin

8) No oral beta-lactam in the U.S. possesses clinically relevant activity against________.
   A) MRSA or P. aeruginosa
   B) Streptococcus
   C) Staphylococcus
   D) Clostridium

9) Against which of the following pathogens would oral TMP-SMX NOT be effective?
   A) E. coli
   B) P. aeruginosa
   C) MSSA
   D) CA-MRSA

10) Duration of intravenous antimicrobial treatment of acute osteomyelitis should be:
    A) At least 6–8 weeks, irrespective of the pathogen
    B) Based on patient-specific risk factors, clinical response, laboratory parameter normalization, and evaluation of collateral impact of long-term venous access
    C) Contingent solely on normalization of CRP and ESR
    D) Length of hospital stay

SEE ANSWER SHEET ON PAGE 145.

The author(s) certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.
Enrollment/Testing Information and Answer Sheet

Note: If you are mailing your answer sheet, you must complete all info. on the front and back of this page and mail with your credit card information to: Program Management Services, P.O. Box 490, East Islip, NY 11730.

**TESTING, GRADING AND PAYMENT INSTRUCTIONS**

1. Each participant achieving a passing grade of 70% or higher on any examination will receive an official computer form stating the number of CE credits earned. This form should be safeguarded and may be used as documentation of credits earned.

2. Participants receiving a failing grade on any exam will be notified and permitted to take one re-examination at no extra cost.

3. All answers should be recorded on the answer form below. For each question, decide which choice is the best answer, and circle the letter representing your choice.

4. Complete all other information on the front and back of this page.

5. Choose one of the 3 options for test grading: mail-in, fax, or phone. To select the type of service that best suits your needs, please read the following section, “Test Grading Options”.

**TEST GRADING OPTIONS**

**Mail-In Grading**

To receive your CME certificate, complete all information and mail with your credit card information to: Program Management Services, P.O. Box 490, East Islip, NY 11730. PLEASE DO NOT SEND WITH SIGNATURE REQUIRED, AS THESE WILL NOT BE ACCEPTED.

In the event you require additional CME information, please contact PMS, Inc., at 1-631-563-1604.

**Facsimile Grading**

To receive your CME certificate and fax within 48 hours, call 1-800-232-4422 from 10 a.m. to 5 p.m. EST, Monday through Friday. Your CME certificate will be dated the same day you call and mailed within 48 hours. There is a $2.95 charge for this service if you are currently enrolled in the annual 10-exam CME program (and this exam falls within your enrollment period), and this fee can be charged to your Visa, Mastercard, American Express, or Discover. If you are not currently enrolled, the fee is $29 per exam. When you call, please have ready:

1. Program number (Month and Year)
2. The answers to the test
3. Credit card information

**Phone-In Grading**

You may also complete your exam by using the toll-free service. Call 1-800-232-4422 from 10 a.m. to 5 p.m. EST, Monday through Friday. Your CME certificate will be dated the same day you call and mailed within 48 hours. There is a $2.95 charge for this service if you are currently enrolled in the annual 10-exam CME program (and this exam falls within your enrollment period), and this fee can be charged to your Visa, Mastercard, American Express, or Discover. If you are not currently enrolled, the fee is $29 per exam. When you call, please have ready:

1. Program number (Month and Year)
2. The answers to the test
3. Credit card information

Please print clearly...Certificate will be issued from information below.

**ENROLLMENT FORM & ANSWER SHEET**

Name ________________________________ Email Address ________________________________

Please Print: ___________________________ MI ___________________________ LAST

Address __________________________________________________________

City_________________________________________ State_______________________ Zip____________________

Charge to: _____ Visa _____ MasterCard _____ American Express

Card #_________________________________________ Exp. Date____________________ Zip for credit card________________

Note: Credit card is the only method of payment. Checks are no longer accepted.

Signature________________________________ Email Address ___________________________ Daytime Phone____________________

State License(s)___________________________ Is this a new address? Yes________ No________

Check one:  

____ I am currently enrolled. (If faxing or phoning in your answer form please note that $2.95 will be charged to your credit card.)

____ I am not enrolled. Enclosed is my credit card information. Please charge my credit card $29.00 for each exam submitted. (plus $2.95 for each exam if submitting by fax or phone).

____ I am not enrolled and I wish to enroll for 10 courses at $249.00 (thus saving me $41 over the cost of 10 individual exam fees). I understand there will be an additional fee of $2.95 for any exam I wish to submit via fax or phone.

Over, please
EXAM #10/20
Medical Management of Osteomyelitis
(Caputo and Raja)

Circle:
1. A B C D 6. A B C D
2. A B C D 7. A B C D
3. A B C D 8. A B C D
5. A B C D 10. A B C D

Medical Education Lesson Evaluation

<table>
<thead>
<tr>
<th>Strongly agree</th>
<th>Agree</th>
<th>Neutral</th>
<th>Disagree</th>
<th>Strongly disagree</th>
</tr>
</thead>
</table>

1) This CME lesson was helpful to my practice ____
2) The educational objectives were accomplished ____
3) I will apply the knowledge I learned from this lesson ____
4) I will make changes in my practice behavior based on this lesson ____
5) This lesson presented quality information with adequate current references ____
6) What overall grade would you assign this lesson?
   A  B  C  D
7) This activity was balanced and free of commercial bias.
   Yes _____ No _____
8) What overall grade would you assign to the overall management of this activity?
   A  B  C  D

How long did it take you to complete this lesson?
_____ hour _____ minutes

What topics would you like to see in future CME lessons?
Please list:
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________